Pharmacists are likely to see Parkinson's patients or their caregiver frequently because of the disease's slow and chronic course. Pharmacists need to e particularly vigilant about medication interactions and ensure doing changes are gradual.
Ms. Wick is a senior clinical research pharmacist at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland. The views expressed are those of the author and not those of any government agency.
James Parkinson’s 1817 “Essay on the Shaking Palsy,”1,2 we have learned that patients with Parkinson’s disease (PD) lose cells in the substantia nigra, and striatum dopamine concentrations are markedly decreased. Arvid Carlsson, ML, MD, earned the Nobel Prize for Medicine in 2000 for his trials of levodopa in PD patients.3 Researchers have identified genetic mutations, abnormal handling of misfolded proteins by the ubiquitin— proteasome and the autophagy– lysosomal systems, increased oxidative stress, mitochondrial dysfunction, inflammation, and other pathogenic mechanisms.4,5
Clinical Presentation: TRAP
The TRAP acronym describes PD’s 4 most salient features:
• Tremor at rest
• Akinesia (or bradykinesia)
• Postural instability
Nonmotor symptoms are common and underappreciated.6 These include autonomic dysfunction (orthostatic hypotension, sweating, and sphincter dysfunction), cognitive/neurobehavioral disorders, and sensory and sleep abnormalities. 7
Rest tremor, easily recognized, is unilateral, occurs at frequencies between 4 and 6 Hz, is almost always prominent in distal extremities, and disappears with action and during sleep. Supination—pronation (“pill-rolling”) tremors spread from one hand to the other. Rest tremor can also involve the lips, chin, jaw, and legs. The neck, head, or voice are usually uninvolved.8 Among patients, tremor patterns vary and change over time.9
Rigidity is increased resistance, usually demonstrated by the “cogwheel” phenomenon—circular jerking rigidity in flexion and extension in a background of tremor, which continues throughout an entire range of movement.10 It can be painful, and painful shoulder is one of PD’s most frequent initial manifestations.11,12 Rigidity of the neck and trunk may cause postural deformities, generally late in the disease.13 One of PD’s most disabling symptoms, acute immobility episodes (or freezing), may make patients unable to rise from a chair, speak, or walk; although these often occur toward the end of the dose interval, they can be spontaneous and unpredictable.14
Bradykinesia, or slow movement, is PD’s most characteristic clinical feature. Initially, it creates difficulty with ordinary activities and slow movement and reaction times.15,16 It progresses to difficulty in planning, initiating, and executing movement; patients also have trouble performing sequential and simultaneous tasks.17 Fine motor tasks (eg, buttoning, holding a pen or eating utensils) suffer. Eventually, patients become “frozen” and cannot gesture, drool because of impaired swallowing, 18 lose facial expression, and walk rigidly. Paradoxically, patients who become excited or alarmed may be able to move quickly to catch a ball (or may run if someone screams “fire”). Bradykinesia appears to be related to degree of dopamine deficiency.19
Postural instability occurs as the patient loses postural reflexes, often at the late stages of PD. Postural instability frequently causes falls, many of which lead to hip fractures.20
Treating Parkinson’s: Medication
The Table describes drugs used in PD. Clinicians work with individuals and consider each drug’s relative efficacy and adverse effect profile; the patient’s comorbidity, employment status, and preference; and experience. For obvious reasons, drug treatment usually begins with dopamine replacement therapy. Levodopa (L-dopa), dopamine’s metabolic precursor, prescribed with a peripheral decarboxylase inhibitor to reduce the incidence of nausea and vomiting, generally provides the best symptomatic relief with the fewest short-term adverse effects.21
For resistant tremor, clinicians may use anticholinergic drugs as an L-dopa alternative, but they are usually ineffective for
other parkinsonism features.21 The dopamine agonists or the monoamine oxidase B (MAO-B) inhibitors can be used early as monotherapy to improve symptoms. They block dopamine breakdown and extend L-dopa dose’s duration of action. In patients unresponsive to L-dopa, or in those who are not responding as well as they had been, dopamine agonists as adjunct therapy can allow an L-dopa dose reduction. Selegiline’s metabolites— amphetamine and methamphetamine— may inhibit dopamine reuptake and enhance dopamine release. Rasagiline is a second-generation MAO-B inhibitor. Unlike selegiline, it lacks amphetamine metabolites.21,22
Catechol-O-methyl transferase inhibitors increase the peripheral half-life of levodopa, thereby delivering more levodopa to the brain over a longer period of time.21,22
Implications for Pharmacists
Because of PD’s slow and chronic course, pharmacists will see these patients or their caregivers frequently. Pharmacists need to be particularly vigilant about medication interactions and ensure dosing changes are gradual rather than abrupt. They should also ask often about swallowing difficulties and offer alternatives when patients begin to have difficulty with oral medications. Advising patients to always ask before crushing oral dosage forms from new prescriptions should be an everyvisit reminder. Also, pharmacists must anticipate that childproof closures and blister packs will present challenges for the PD patient, and take appropriate action proactively. %u25A0
1. Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 2002;14:223—36.
2. Kempster PA, Hurwitz B, Lees AJ. A new look at James Parkinson’s essay on the shaking palsy. Neurology 2007;69:482—5.
3. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961;73:787—8.
4. Jankovic J, Tolosa E, McNaught KSP, Jenner P, Olanow CW. Protein mishandling: Role of the ubiquitin proteasome system in the pathogenesis of Parkinson’s disease. In: Jankovic J, Tolosa E, eds. Parkinson’s disease and movement disorders. Philadelphia: Lippincott Williams and Wilkins, 2007:33—49.
5. Pan T, Kondo S, Le W, et al. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008 (Epub ahead of print).
6. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol. 2010 Feb 6. [Epub ahead of print]
7. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;63:584—9.
8. Uluduz D, Ertürk O, Kenangil G, Ozekmekçi S, Ertan S, Apaydin H, Erginöz E. Apraxia in Parkinson's disease and multiple system atrophy. Eur J Neurol. 2009 Dec 30. [Epub ahead of print]
9. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993;50:140—8.
10. Broussolle E, Krack P, Thobois S, et al. Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord 2007;22:909—14.
11. Riley D, Lang AE, Blair RD, et al. Frozen shoulder and other shoulder disturbances in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989;52:63—6.
12. Stamey WP, Jankovic J. Shoulder pain in Parkinson’s disease. Mov Disord 2007;22:S247—8.
13. Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006;21:1856—63.
14. Boghen D. Apraxia of lid opening: a review. Neurology 1997;48:1491—4.
15. Cooper JA, Sagar HJ, Tidswell P, et al. Slowed central processing in simple and go/no-go reaction time tasks in Parkinson’s disease. Brain 1994;117:517—29.
16. Giovannoni G, van Schalkwyk J, Fritz VU, et al. Bradykinesia akinesia inco-ordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function. J Neurol Neurosurg Psychiatry 1999;67:624—9.
17. Berardelli A, Rothwell JC, Thompson PD, et al. Pathophysiology of bradykinesia in Parkinson’s disease. Brain 2001;124:2131—46.
18. Bagheri H, Damase-Michel C, Lapeyre-Mestre M, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 1999;22:213—15.
19. Vingerhoets FJG, Schulzer M, Calne DB, et al. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58—64.
20. Williams DR, Watt HC, Lees AJ . Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 2006;77:468—73.
21. Grosset DG, Macphee GJ, Nairn M; Guideline Development Group. Diagnosis and pharmacological management of Parkinson's disease: summary of SIGN guidelines. BMJ. 2010 Jan 12;340:b5614.
22. MICROMEDEX® 1.0 (Healthcare Series). Available at http://www.thomsonhc.com/hcs/librarian/. Accessed February 8, 2010.